Drug research

Tenapanor

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as IBSRELA; Ibsrela; RDX5791, AZD1722

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CNCT05905926	Ardelyx	Phase 3	Enrolling by invitation	2031-07Estimated
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsNCT06553547	Ardelyx	Phase 2	Completed	2026-07-07Actual
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisNCT03427125	Ardelyx	Phase 3	Completed	2019-11-15Actual

ArdelyxEnrolling by invitationPrimary completion: 2031-07 · Estimated

Trial details

ArdelyxCompletedPrimary completion: 2026-07-07 · Actual

Trial details

ArdelyxCompletedPrimary completion: 2019-11-15 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.